Context Therapeutics (NASDAQ:CNTX) Posts Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Context Therapeutics (NASDAQ:CNTX) issued its quarterly earnings results on Wednesday. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11), Zacks reports.

Context Therapeutics Stock Down 6.7 %

Context Therapeutics stock traded down $0.14 during trading hours on Friday, hitting $1.95. The stock had a trading volume of 339,093 shares, compared to its average volume of 295,287. The stock’s 50-day moving average price is $2.09 and its 200-day moving average price is $2.06. Context Therapeutics has a 12-month low of $0.77 and a 12-month high of $2.75.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Context Therapeutics in a research note on Monday, September 23rd.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.